Invesco
EGRX

Invesco’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Invesco’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-82,775
Closed -$309K – 3857
2024
Q3 		$309K Buy
82,775
+351
+0.4% +$1.68K ﹤0.01% 3407
2024
Q2 		$462K Sell
82,424
-34,828
-30% -$152K ﹤0.01% 3300
2024
Q1 		$614K Buy
117,252
+100,487
+599% +$552K ﹤0.01% 3230
2023
Q4 		$87.7K Sell
16,765
-1,063
-6% -$10.5K ﹤0.01% 3703
2023
Q3 		$281K Buy
17,828
+104
+0.6% +$1.87K ﹤0.01% 3475
2023
Q2 		$345K Sell
17,724
-51,034
-74% -$1.21M ﹤0.01% 3439
2023
Q1 		$1.95M Sell
68,758
-3,179
-4% -$94.4K ﹤0.01% 2642
2022
Q4 		$2.1M Buy
71,937
+4,113
+6% +$131K ﹤0.01% 2630
2022
Q3 		$1.79M Buy
67,824
+403
+0.6% +$14.8K ﹤0.01% 2684
2022
Q2 		$3M Buy
67,421
+1,444
+2% +$66.3K ﹤0.01% 2532
2022
Q1 		$3.27M Sell
65,977
-2,678
-4% -$129K ﹤0.01% 2583
2021
Q4 		$3.5M Sell
68,655
-1,033
-1% -$53.5K ﹤0.01% 2579
2021
Q3 		$3.89M Sell
69,688
-247,632
-78% -$12.2M ﹤0.01% 2521
2021
Q2 		$13.6M Sell
317,320
-4,722
-1% -$195K ﹤0.01% 1865
2021
Q1 		$13.4M Buy
322,042
+10,408
+3% +$483K ﹤0.01% 1785
2020
Q4 		$14.5M Sell
311,634
-110,857
-26% -$5.18M ﹤0.01% 1606
2020
Q3 		$17.9M Sell
422,491
-53,662
-11% -$2.35M 0.01% 1358
2020
Q2 		$22.8M Buy
476,153
+151,963
+47% +$7.58M 0.01% 1228
2020
Q1 		$14.9M Sell
324,190
-93,026
-22% -$4.67M 0.01% 1334
2019
Q4 		$25.1M Buy
417,216
+62,912
+18% +$3.75M 0.01% 1300
2019
Q3 		$20M Sell
354,304
-48,488
-12% -$2.73M 0.01% 1411
2019
Q2 		$22.4M Buy
402,792
+134,931
+50% +$7.04M 0.01% 1365
2019
Q1 		$13.5M Sell
267,861
-23,281
-8% -$1.04M ﹤0.01% 1442
2018
Q4 		$11.7M Sell
291,142
-258,922
-47% -$13.3M ﹤0.01% 1452
2018
Q3 		$38.1M Buy
550,064
+126,247
+30% +$9.57M 0.01% 962
2018
Q2 		$32.1M Buy
423,817
+24,048
+6% +$1.51M 0.01% 1011
2018
Q1 		$21.1M Sell
399,769
-41,853
-9% -$2.43M 0.01% 1144
2017
Q4 		$23.6M Sell
441,622
-37,690
-8% -$2.1M 0.01% 1129
2017
Q3 		$28.6M Buy
479,312
+31,062
+7% +$1.88M 0.01% 1011
2017
Q2 		$35.4M Buy
448,250
+287,891
+180% +$23.5M 0.01% 935
2017
Q1 		$13.3M Buy
160,359
+9,163
+6% +$681K ﹤0.01% 1389
2016
Q4 		$12M Buy
151,196
+11,687
+8% +$849K ﹤0.01% 1416
2016
Q3 		$9.77M Buy
139,509
+30,664
+28% +$1.7M ﹤0.01% 1526
2016
Q2 		$4.22M Sell
108,845
-23,038
-17% -$959K ﹤0.01% 2038
2016
Q1 		$5.34M Sell
131,883
-34,647
-21% -$2.2M ﹤0.01% 1826
2015
Q4 		$14.8M Buy
166,530
+5,798
+4% +$458K 0.01% 1293
2015
Q3 		$11.9M Buy
160,732
+125,879
+361% +$10.5M 0.01% 1378
2015
Q2 		$2.82M Buy
34,853
+33,253
+2,078% +$2.17M ﹤0.01% 2397
2015
Q1 		$67K Buy
1,600
+600
+60% +$17K ﹤0.01% 3873
2014
Q4 		$16K Buy
+1,000
New +$12.8K ﹤0.01% 3968

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $469M AUM 19.1% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Invesco's EGRX Position: Q4 2024 in Review

Invesco sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 82,775 shares — an estimated $309K sold.

Invesco first reported a position in EGRX in Q4 2014 and held it in 40 quarters. The position peaked at $38.1M in Q3 2018. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Invesco reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Invesco sold 82,775 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $309K.
  • Invesco first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2014 and held it in 40 quarters.
  • Invesco's Eagle Pharmaceuticals, Inc. position peaked at $38.1M in Q3 2018.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Invesco's 13F filing for Q4 2024, filed 13 Feb 2025.